GHRS · GH Research PLC
United States · RS rating 43 · As of 2026-11-03
| Price | 20.28 USD |
|---|---|
| 1-day change | -1.1% |
| RS rating (overall / 1M / 3M / 12M) | 43 / 38 / 20 / 81 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 38 / 36 / 36 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +25.8% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +33.8% |
| Market cap (USD) | $1.2B |